Effect of AD-5423 on animal models of schizophrenia: phencyclidine-induced behavioral changes in mice.

Abstract

The antipsychotic efficacy of AD-5423, which has the properties of both a serotonin 5-HT(2) and a dopamine D(2) receptor antagonist, was evaluated using animal models of schizophrenia. Sensitization to phencyclidine (PCP)-induced hyperlocomotion is considered a model of the positive symptoms of schizophrenia, and was significantly antagonized by AD-5423 and haloperidol. The PCP-induced enhancement of immobility induced by the forced swimming test, a model of the negative symptoms of schizophrenia, was attenuated by AD-5423 but not by haloperidol. Since this attenuated effect of AD-5423 was antagonized by DOI, a serotonin 5-HT(2) receptor agonist, it is postulated to be mediated by serotonin 5-HT(2) receptors. These findings suggest that AD-5423 would be clinically effective against both the positive and negative symptoms of schizophrenia.

• Authors: T Nagai, Y Noda, T Une, K Furukawa, H Furukawa, Q M Kan, T Nabeshima
• Journal: Neuroreport (Neuroreport) Vol. 14 Issue 2 Pg. 269-72 (Feb 10 2003) ISSN: 0959-4965 [Print] England
• PMID: 12598744 (Publication Type: Journal Article)

Chemical References

• Piperazines
• Piperidines
• blonanserin
• Phencyclidine

Topics

• Animals
• Disease Models, Animal
• Immobilization (physiology)
• Male
• Mice
• Motor Activity (drug effects, physiology)
• Phencyclidine (toxicity)
• Piperazines (therapeutic use)
• Piperidines (therapeutic use)
• Schizophrenia (chemically induced, drug therapy, physiopathology)